ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0637

DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
Abstract Number: 0638

Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
Abstract Number: 0639

Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
Abstract Number: 0640

Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
Abstract Number: 0641

Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Abstract Number: 0642

Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Abstract Number: 0644

Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Abstract Number: 0645

Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Abstract Number: 0646

A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Abstract Number: 0647

Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus: an open-label pilot study
Abstract Number: 0648

Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Abstract Number: 0649

Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Abstract Number: 0650

Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Abstract Number: 0651

The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
Abstract Number: 0652

Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].